46.73
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
Gastroparesis Market Growth to Accelerate in Forecast Period - openPR.com
KLP Kapitalforvaltning AS Invests $646,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Trexquant Investment LP Purchases 95,418 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Thrivent Financial for Lutherans Sells 18,759 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Pictet Asset Management Holding SA Increases Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
(PTCT) Technical Data - news.stocktradersdaily.com
PTC Therapeutics (NASDAQ:PTCT) Stock Price Down 8.8% After Analyst Downgrade - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Cut to $75.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Raymond James Financial Inc. Makes New $2.20 Million Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Natixis Advisors LLC Acquires New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
PTC Therapeutics says Duchenne drug Translarna is no longer authorized in EU - MSN
Cibc World Markets Corp Acquires Shares of 7,127 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StreetInsider.com
PTC Therapeutics faces EC setback on Translarna in Europe By Investing.com - Investing.com South Africa
PTC Therapeutics Faces EU Setback on Translarna - TipRanks
PTC Therapeutics says EC will not renew market authorization for muscle disorder drug - MarketScreener
PTC Therapeutics stock slips as EU ends Translarna nod (PTCT) - Seeking Alpha
PTC Therapeutics faces EC setback on Translarna in Europe - Investing.com
PTC Therapeutics (PTCT) Faces EU Setback for DMD Drug Translarna - GuruFocus
European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder - Benzinga
PTC Therapeutics says EC not to renew market authorization for muscle disorder drug - MarketScreener
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe - Quantisnow
PTC Therapeutics Loses EU Authorization for Translarna in Duchenne Muscular Dystrophy - MarketScreener
PTC Therapeutics: European Commission Decides To Adopt CHMP Negative Opinion On Translarna - Nasdaq
PTC Therapeutics says European Commission will remove muscle disorder drug - MarketScreener
PTC Therapeutics Provides Regulatory Update On Translarna(TM) (Ataluren) In Europe - MarketScreener
Sector Gamma AS Purchases Shares of 65,250 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Proficio Capital Partners LLC Invests $758,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
A Shareholder alert for PTC Therapeutics, Inc was sent by Bronstein, Gewirtz and Grossman, LLC to Lead Class Action Lawsuit! - ACCESS Newswire
AlphaQuest LLC Has $49,000 Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Sets New 52-Week HighShould You Buy? - MarketBeat
First Week of May 16th Options Trading For PTC Therapeutics - Nasdaq
Leigh Syndrome Treatment Market Size in 7MM is expected to grow - openPR
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Stephanie Okey Sells 5,000 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
Insider Sell Alert: Eric Pauwels Sells Shares of PTC Therapeutics Inc (PTCT) - GuruFocus
Charles Schwab Investment Management Inc. Trims Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics reports progress in PKU treatment study By Investing.com - Investing.com Australia
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July - Benzinga
PTC Therapeutics reports progress in PKU treatment study - Investing.com India
PTCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PTC Therapeutics, Inc Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JPMorgan Chase & Co. Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $78.00 - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month High After Analyst Upgrade - MarketBeat
PTC Therapeutics chief business officer sells $630,104 in stock - Investing.com India
PTC Therapeutics chief business officer sells $630,104 in stock By Investing.com - Investing.com UK
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):